---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-003740"
form_type: "8-K"
ticker: "SCNX"
cik: "0001382574"
company_name: "Scienture Holdings, Inc."
filed_at: "2023-02-07T23:59:59+00:00"
generated_at: "2026-06-19T22:43:52.367096+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TRxADE HEALTH receives Nasdaq delisting notice for failure to meet $2.5M equity minimum; hearing requested

## Summary
- Nasdaq notified company on Jan 30, 2023 of failure to meet $2.5M min stockholders' equity after extension granted Oct 17, 2022.
- Company filed hearing request on Feb 6, 2023 with Nasdaq Hearings Panel; delisting stayed pending hearing outcome.
- At hearing, company will propose plan to regain compliance; no guarantee of acceptance or eventual relisting.
- If delisted, trading liquidity and ability to raise capital could be materially impaired.

## SEC filing metadata
- accession: 0001493152-23-003740
- form_type: 8-K
- ticker: SCNX
- cik: 0001382574
- company_name: Scienture Holdings, Inc.
- filed_at: 2023-02-07T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1382574/000149315223003740/0001493152-23-003740-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1382574/000149315223003740/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-003740
- JSON: https://secwatch.observer/filing/0001493152-23-003740.json
- Plain text: https://secwatch.observer/filing/0001493152-23-003740.txt

## Key facts
- Listing & Compliance Notices
  Scienture Holdings, Inc. received a nasdaq delisting notice notice regarding stockholders equity.
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: stockholders equity
  source text: February 6, 2023, the Company submitted a hearing request to the Nasdaq Hearings Panel (the “ Panel ”), which request will stay any delisting action by the Staff at least until the hearing process concludes and any extension granted by the Panel expires. At the Panel hearing, the Company intends to present a plan to regain compliance with the minimum stockholders’ equity requirement. In the interim, the Company’s common stock will continue to trade on Nasdaq under the symbol “ MEDS ” at least pending the ultimate conclusion of the hearing process. There can be no assurance that the Company’s p
  evidence_url: https://www.sec.gov/Archives/edgar/data/1382574/000149315223003740/0001493152-23-003740-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.